| Literature DB >> 33206059 |
Peter Malliaras1, Kate Cridland1, Ruben Hopmans1, Simon Ashton1, Chris Littlewood2, Richard Page3, Ian Harris4,5,6, Helen Skouteris7, Terry Haines8.
Abstract
BACKGROUND: Rotator cuff-related shoulder pain (RCRSP) is a common and disabling musculoskeletal condition. Internet-based and telerehabilitation delivery of recommended care may improve access to care and improve adherence and outcomes.Entities:
Keywords: feasibility; internet-delivered intervention; pain; pilot; randomized controlled trial; rotator cuff; shoulder; telemedicine; telerehabilitation; tendinopathy
Mesh:
Year: 2020 PMID: 33206059 PMCID: PMC7710452 DOI: 10.2196/24311
Source DB: PubMed Journal: JMIR Mhealth Uhealth ISSN: 2291-5222 Impact factor: 4.773
Figure 1External rotation and elevation exercises.
Demographic information of study participants.
| Demographic factor | Advice only (n=12) | Recommended care (n=12) | Recommended care and telerehabilitation (n=12) | |
| Age (years), mean (SD) | 53.7 (11.5) | 51.3 (13.7) | 56.6 (11.0) | |
| Female, n (%) | 11 (92) | 10 (83) | 11 (92) | |
| Height (cm), mean (SD) | 166.3 (7.0) | 170.8 (11.8) | 165.1 (8.2) | |
| Mass (kg), mean (SD) | 84.3 (24.7) | 74.9 (16.9) | 76.4 (12.6) | |
| BMI (kg/m²), mean (SD) | 30.9 (10.3) | 25.9 (5.7) | 28.0 (4.2) | |
| Employed, n (%) | 6 (50) | 8 (67) | 5 (42) | |
|
|
|
|
| |
|
| Urban | 7 (58) | 9 (75) | 9 (75) |
|
| Other urban | 4 (25) | 2 (17) | 3 (25) |
|
| Rural | 1 (8) | 1 (8) | 0 (0) |
| Affected/worst side is right side, n (%) | 8 (67) | 6 (50) | 7 (58) | |
| Duration of symptoms (weeks), mean (SD) | 27.6 (17.1) | 42.5 (17.7) | 33.8 (20.0) | |
| Prior exercise treatment, n (%) | 8 (67) | 8 (67) | 9 (75) | |
| Prior activity modification, n (%) | 2 (17) | 5 (42) | 6 (50) | |
| Prior shoulder imaging, n (%) | 3 (25) | 6 (50) | 3 (25) | |
| SPADI, mean (SD) | 30.6 (17.7) | 37.3 (16.7) | 41.8 (19.0) | |
| Worst pain in the previous week, mean (SD) | 5.4 (2.8) | 7.5 (2.0) | 6.3 (3.8) | |
|
|
|
|
| |
|
| Osteoarthritis | 5 (42) | 0 (0) | 3 (25) |
|
| Rheumatoid arthritis | 0 (0) | 2 (17) | 0 (0) |
|
| Inflammatory bowel disease | 1 (8) | 0 (0) | 0 (0) |
|
| Fibromyalgia | 0 (0) | 2 (17) | 0 (0) |
|
| Hypertension | 1 (8) | 0 (0) | 1 (8) |
|
| Hypercholesterolemia | 0 (0) | 2 (17) | 5 (42) |
|
| Diabetes | 1 (8) | 1 (8) | 3 (25) |
Figure 2Consolidated Standards of Reporting Trials (CONSORT) flow diagram. tele: telerehabilitation.
Figure 3Exercise adherence in patients receiving recommended care and recommended care with telerehabilitation.
Adverse events and co-interventions.
| Adverse event or co-intervention measure | Advice only | Recommended care | Recommended care and telerehabilitation | |
|
|
|
| ||
|
| Participants reporting adverse event | 6 (50) | 4 (33) | 6 (50) |
|
| Total number of adverse events | 10 | 7 | 8 |
|
| Mild | 7 (70) | 4 (57) | 6 (75) |
|
| Moderate | 3 (30) | 3 (43) | 1 (12) |
|
| Serious | 0 (0) | 0 (0) | 1 (12) |
|
|
|
| ||
|
| Participants using co-interventions | 2 (17) | 2 (17) | 2 (17) |
|
| Total number of co-interventions | 14 | 16 | 15 |
|
| Therapy sessions | 9 (64) | 9 (56) | 9 (60) |
|
| Other interventions | 1 (7) | 5 (31) | 3 (20) |
|
| Episodes of medication use | 4 (29) | 2 (13) | 3 (20) |
|
| Participants using medication, n (%) | 2 (17) | 2 (17) | 2 (17) |
|
| Total number of days of medication usea | 27 | 14 | 24 |
aFrom a total of 1080 person-days (12 participants x 90-day study period).
Figure 4Global rating of change.
Secondary outcomes (reported as mean [SD]).
| Outcome | Advice only | Recommended care | Recommended care and telerehabilitation | |
|
|
|
|
| |
|
| Baseline | 30.6 (17.7) | 37.3 (16.7) | 41.8 (19.1) |
|
| Week 6 | 32.9 (19.9) | 27.3 (18.5) | 15.0 (9.5) |
|
| Week 12 | 26.6 (22.3) | 21.7 (17.8) | 12.9 (6.9) |
|
| Mean difference at 6 weeks (95% CI) | 2.3 (–9.5 to 14.1) | –14.0 (–26.7 to –1.3) | –26.9 (–39.2 to –14.5) |
|
| Mean difference at 12 weeks (95% CI) | –4.8 (–20.3 to 10.8) | –16.0 (–26.0 to –6.0) | –28.9 (–40.9 to –28.7) |
|
| SMDb baseline-week 6 | 0.1 | 0.8 | 1.4 |
|
| SMD baseline-week 12 | 0.3 | 0.9 | 1.4 |
|
|
|
|
| |
|
| Baseline | 56.8 (17.9) | 51.6 (22.4) | 59.7 (21.1) |
|
| Week 6 | 55.7 (22.2) | 41.5 (22.2) | 31.9 (23.1) |
|
| Week 12 | 41.8 (23.1) | 44.8 (28.1) | 28.1 (25.6) |
|
| Mean difference at 6 weeks ( | –0.2 (–11.3 to 10.9) | –9.3 (–34.9 to 16.29) | –26.8 (–44.8 to –8.9) |
|
| Mean difference at 12 weeks, (95% CI) | –15.8 (–33.1 to 1.5) | –3.2 (–19.7 to 13.4) | –31.6 (–49.89 to –13.28) |
|
| SMD baseline-week 6 | 0.1 | 0.6 | 1.0 |
|
| SMD baseline-week 12 | 0.2 | 0.6 | 1.0 |
|
|
|
|
| |
|
| Baseline | 36.0 (7.0) | 35.2 (5.8) | 35.5 (6.7) |
|
| Week 6 | 37.3 (6.6) | 31.5 (8.9) | 32.6 (7.5) |
|
| Week 12 | 36.3 (6.5) | 30.6 (5.7) | 31.1 (6.6) |
|
| Mean difference at 6 weeks (95% CI) | –0.2 (–4.2 to 3.8) | –4.8 (–8.8 to –0.8) | –3.6 (–7.2 to 0.1) |
|
| Mean difference at 12 weeks, (95% CI) | –1.9 (–5.9 to 2.1) | –5.0 (–7.0 to –3.0) | –4.4 (–8.8 to –0.1) |
|
| SMD baseline-week 6 | 0.0 | 0.6 | 0.5 |
|
| SMD baseline-week 12 | 0.3 | 0.8 | 0.6 |
|
|
|
|
| |
|
| Baseline | 7.3 (9.2) | 4.6 (5.8) | 4.8 (4.1) |
|
| Week 6 | 8.8 (10.5) | 6.0 (10.5) | 3.7 (3.3) |
|
| Week 12 | 5.1 (0.5 to 9.7) | 2.7 (1.1 to 4.2) | 4.0 (1.0 to 7.0) |
|
| Mean difference at 6 weeks (95% CI) | 0.6 (–1.1 to 2.3) | 0.1 (–1.8 to 2.0) | –1.6 (–3.1 to 0.0) |
|
| Mean difference at 12 weeks (95% CI) | –3.4 (–7.3 to 0.5) | –2.0 (–4.6 to 0.6) | –0.8 (–3.3 to 1.6) |
|
| SMD baseline-week 6 | 0.0 | 0.0 | 0.4 |
|
| SMD baseline-week 12 | 0.4 | 0.5 | 0.2 |
|
|
|
|
| |
|
| Baseline | 50.4 (9.4) | 50.1 (9.3) | 52.3 (6.9) |
|
| Week 6 | 49.7 (6.4) | 51 (7.6) | 55.1 (4.1) |
|
| Week 12 | 50.5 (7.9) | 54.8 (6.5) | 55.6 (5.8) |
|
| Mean difference at 6 weeks (95% CI) | –1.1 (–5.1 to 2.9) | 1.7 (–7.2 to 10.5) | 3.6 (0.8 to 6.3) |
|
| Mean difference at 12 weeks, (95% CI) | 1.3 (–4.1 to 6.7) | 4.2 (–1.6 to 9.9) | 3.3 (1.0 to 5.6) |
|
| SMD baseline-week 6 | 0.1 | 0.2 | 0.6 |
|
| SMD baseline-week 12 | 0.2 | 0.5 | 0.5 |
|
|
|
|
| |
|
| Baseline | 0.76 (0.11) | 0.74 (0.13) | 0.74 (0.12) |
|
| Week 6 | 0.73 (0.12) | 0.74 (0.12) | 0.77 (0.11) |
|
| Week 12 | 0.73 (0.09) | 0.77 (0.13) | 0.78 (0.07) |
|
| Mean difference at 6 weeks (95% CI) | –0.02 (–0.10 to 0.06) | 0.02 (–0.08 to 0.12) | 0.05 (–0.02 to 0.12) |
|
| Mean difference at 12–weeks, (95% CI) | –0.02 (–0.14 to 0.10) | 0.01 (–0.10 to 0.12) | 0.03 (–0.02 to 0.09) |
|
| SMD baseline-week 6 | 0.2 | 0.2 | 0.4 |
|
| SMD baseline-week 12 | 0.2 | 0.1 | 0.3 |
aSPADI: shoulder pain and disability index.
bSMD: standardized mean difference.
cTSK: Tampa Scale for Kinesiophobia.
dPCS: Pain Catastrophizing Scale.
ePSEQ: Pain Self-Efficacy Questionnaire.
fEQ5D: EuroQol 5D-5L.
Figure 5Knowledge test change over time. post: postintervention; pre: preintervention; wk: week.